Short answer
Gossamer Bio, Inc. (GOSS) filed an 8-K current report with the SEC on September 11, 2026 reporting Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). 1-for-80 reverse split effective September 10, 2026, consolidating every 80 shares into 1.
Gossamer Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- 1-for-80 reverse split effective September 10, 2026, consolidating every 80 shares into 1
- Authorized common shares reduced from 4,000,000,000 to 50,000,000
- Nasdaq compliance objective: $1.00 minimum closing bid for 10 consecutive business days before October 5, 2026
- Convertible notes, warrants, and equity awards proportionately adjusted, preserving holders’ economic terms
- Split-adjusted trading begins September 11 under GOSS with new CUSIP 38341P 201
Item 8.01 · Other Events
- Reverse stock split and authorized share reduction became effective September 11, 2026
- Split-adjusted common-stock trading expected to begin following effectiveness
- Corporate action intended to help restore Nasdaq minimum bid-price compliance
- Continued Nasdaq Global Select Market listing remains uncertain
- Potential risks include sustained low share price, increased volatility, and operational or reputational effects
Item EX-99.1 · Exhibit EX-99.1
- 1-for-80 reverse split effective September 10, 2026; split-adjusted Nasdaq trading began September 11 under “GOSS”
- Split targets Nasdaq’s $1.00 minimum bid requirement; compliance deadline October 5, 2026
- Authorized common shares reduced from 4 billion to 50 million, limiting future issuance capacity
- Convertible notes, warrants, equity awards, and exercise prices proportionately adjusted
- Continued Nasdaq listing remains uncertain if shares fail to maintain $1.00 for 10 consecutive business days
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Gossamer Bio, Inc. 8-K filings
Get the next GOSS 8-K as it lands
Follow GOSS for push alerts, or ask the research agent what this filing means.